ResearchRSSMay 15
Cereno, PHA Europe partner on patient-centered PH drug design
A company called Cereno Scientific is working with PHA Europe & Global to design new pulmonary hypertension medicines in a way that includes patient input. Instead of just scientists deciding how to develop drugs, patients with pulmonary hypertension will have a say in the process from start to finish. This partnership means the final medications may work better for the people who actually need them.
WHY IT MATTERSPatients with pulmonary hypertension will now have direct input into how new treatments are designed, potentially resulting in drugs that better address their real-world needs and concerns.